Submitted to: Brucellosis Research National Conference Proceedings
Publication Type: Abstract Only
Publication Acceptance Date: 11/10/1996
Publication Date: N/A
Citation: N/A Interpretive Summary:
Technical Abstract: Polled Hereford heifers were vaccinated SC at 6 months of gestation with 10*9 CFU SRB51 (n=5), 3 x 10*8 CFU S19 (n=5), or sterile saline (n=2). Signs of abortion, arthritis, or anaphylaxis were not seen in either vaccine group and lesions consistent with brucellosis were not seen at necropsy of full term heifers. At necropsy, 2/5 SRB51-vaccinates had SRB51 in superficial cervical lymph nodes in the region of vaccination. Bacteriologic culture did not recover SRB51 or S19 from any other tissues or fluids from heifers or their calves. SRB51-vaccinates did not develop antibody titers detected by standard tube agglutination, but did develop titers greater (P<0.05) than S19-vaccinates on a dot ELISA which detects anti-SRB51 antibodies. Lymphocyte blastogenesis assays on maternal PBMC showed proliferative responses to irradiated SRB51 and irradiated S19 in SRB51- and S19-vaccinates which were greater (P<0.05) than that seen in saline-vaccinated controls. These results support the use of SRB51 as a brucellosis vaccine in pregnant cattle, indicating that pregnant cattle can be safely vaccinated SC with 10*9 CFU SRB51 without widespread maternal or fetal infection, placentitis or abortion, and that such vaccination is immunogenic in pregnant cattle inducing both humoral and cell-mediated responses.